替格瑞洛用于急性冠脉综合征患者经皮冠状动脉介入治疗的疗效及安全性

摘要

Objective To study the effects of tigrine on platelet inhibition and major cardiac adverse events in patients with acute coronary syndromes (ACS).Methods Between September 2014 and December 2015,51 patients with acute coronary syndrome patients with ACS underwent PCI treated with tricloprid and were selected as observation group.In the same period,51 patients with ACS underwent PCI treated with clopidogrel were selected as a control group.The ADP-induced platelet inhibition rate,the incidence of major adverse cardiac events and bleeding and difficulty in breathing rate were observed.Results The platelet inhibition rate of the observation group was significantly higher than that of the control group at 1 week and 1 month after treatment.The difference was significant (P＜0.05).Major adverse cardiac events in observation group were significantly less than that in the control group.The difference was significant (P＜0.05).Conclusion The effect of ticagrelor for ACS patients underwent PCI is significant.The incidence of major cardiac adverse events is reduced and the safety is good.%目的 研究替格瑞洛对急性冠脉综合征(ACS)患者血小板抑制率及主要心脏不良事件的影响.方法 将2014年9月～2015年12月期间的51例经皮冠状动脉介入治疗(PCI)术后使用替格瑞洛治疗的ACS病人作为观察组,同时期使用氯吡格雷治疗的行PCI手术的ACS患者51例作为对照组,比较两组治疗后二磷酸腺苷(ADP)诱导的血小板抑制率、主要心脏不良事件发生率以及出血、呼吸困难发生率.结果 治疗后1周及1个月,观察组的血小板抑制率明显高于对照组,组间差异有显著性(P＜0.05);观察组主要心脏不良事件发生率明显低于对照组,组问差异亦有显著性(P＜0.05).结论 替格瑞洛用于行PCI术的ACS病人中,抗血小板效果显著,且能降低主要心脏不良事件的发生率,安全性良好.